Introduction & Objective: Sensor-based glucose monitoring technology may reduce risks of hypoglycemia and DKA by providing people with DM key insights into their glucose variability and trends. This study investigated HbA1c and healthcare resource utilization (HCRU) before and after adoption of flash glucose monitoring in people with DM.
Methods: This longitudinal retrospective cohort study used the IC/ES database of publicly funded administrative health data in Ontario, Canada. The analysis cohort comprised 45,523 people with DM in groups aged < 66 or ≥ 66 years who had a first flash glucose monitoring claim between 16 Sep 2019 and 10 Apr 2021 (index date) and remained active on flash glucose monitoring for 24 months’ follow-up after the index date. ED visits and hospitalization were measured for 12 months before the index date and the last 12 months of follow-up. HbA1c data were taken from the last tests in each period.
Results: Mean HbA1c was significantly improved in both age cohorts (both p <.0001; Table); reductions were seen for both T1DM and T2DM, regardless of treatment used. Mean ED visits and hospitalization rates (overall, for DKA, and for hypoglycemia) improved significantly in both age cohorts, with no change in mean resource intensity weight.
Conclusions: HbA1c levels and HCRU were reduced 12-24 months after sensor-based technology initiation in patients with DM.
S.B. Harris: Consultant; Abbott. Research Support; Boehringer-Ingelheim. Consultant; Dexcom, Inc. Advisory Panel; Eli Lilly and Company. Consultant; Eli Lilly and Company, Novo Nordisk, Sanofi. Research Support; Novartis AG. Consultant; Bayer Inc. R.P. Rabasa-Lhoret: Other Relationship; Abbott, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Dexcom, Inc. Research Support; Diabetes Canada. Other Relationship; Eli Lilly and Company. Research Support; Cystic Fibrosis Canada, Canadian Institutes of Health Research, FFRD - Fondation Francophone pour la Recherche du Diabète. Other Relationship; Janssen Pharmaceuticals, Inc. Research Support; Juvenile Diabetes Research Foundation (JDRF). Other Relationship; Novo Nordisk, GlaxoSmithKline plc. Consultant; HLS Therapeutics Inc., Insulet Corporation. Speaker's Bureau; CPD Networks. Other Relationship; Medtronic. Consultant; Pfizer Inc. Speaker's Bureau; Tandem Diabetes Care, Inc. Other Relationship; Sanofi. Speaker's Bureau; Vertex Pharmaceuticals Incorporated. Research Support; SFD - Société Francophone du Diabète. A. Ratzki-Leewing: Research Support; Sanofi. Advisory Panel; Dexcom, Inc. Consultant; Abbott. Advisory Panel; Sanofi-Aventis U.S. Other Relationship; American Diabetes Association. Consultant; Novo Nordisk, Eli Lilly and Company. Y. Poon: Employee; Abbott.
